Advanced TB Diagnostics

Description

This advanced course will cover advanced topics in TB diagnostics research and implementation, including critical pathway for new TB tests, impact of new tests on clinical decision-making and therapeutic choices, cost-effectiveness in routine programmatic settings, and impact on patient-important outcomes. The course will also cover meta-analysis, mathematical modeling, and cost-effectiveness studies. Panel discussions will cover topics such as value chain for TB diagnostics development, market analyses, market dynamics, target product profiles, and barriers to scale-up of new diagnostics. Participants will include TB survivors, product manufacturers, donors, product development partnerships, policy makers, academics, clinicians, community advocates, public health implementers and National TB Program managers.

 

2017 Advanced TB Diagnostics Agenda

 


Course Director

Madhukar Pai, MD, PhD
Professor of Epidemiology, McGill University
Director, McGill Global Health Programs
Associate Director, McGill International TB Centre

 


Course Faculty

Niaz Banaei, MD – Stanford University
Claudia Denkinger, MD, PhD – FIND
Jim Gallarda, Bill & Melinda Gates Foundation
Adithya Cattamanchi, MD – UCSF
David Dowdy, MD, PhD – Johns Hopkins University
Paul K. Drain, MD, MPH, FACP – University of Washington
Nora Engel, PhD – Maastricht University
Jennifer Furin, MD, PhD – Harvard Medical School
Robyn Lee, PhD – Harvard University
Ruvandhi Nathavitharana, MBBS – BIMDC Harvard Medical School
Marco Schito, PhD – The Critical Path Institute
Samuel Schumacher, MSc, PhD – FIND
Karen Steingart, MD, MPH – Cochrane ID Group
Anita Suresh, MBA, MS – FIND
Cesar Ugarte-Gil, MD, PHD – Universidad Peruana Cayetano Heredia

Faculty are still being confirmed and there may be changes to the above list


 

Content

Diagnosis is one of the biggest gaps in the TB cascade of care. We need better tools for TB diagnosis than what we have today and we need high quality diagnostic studies to evaluate new tools, and to develop evidence-based policies on TB diagnostics. We need data on outcomes such as accuracy of diagnostic algorithms (rather than single tests) and their relative contributions to the healthcare system, incremental value of new tests, impact of new tests on clinical decision-making and therapeutic choices, cost-effectiveness in routine programmatic settings, and impact on patient-important outcomes. Translation of policy into impact requires collecting evidence for scale-up, country-level data on cost-effectiveness and feasibility, implementation research, and local decisions on scale-up, delivery and impact assessment. All of these issues will be covered in this week-long, advanced course.

 


OBJECTIVES

By the end of the course, participants will understand:

  • value chain for TB diagnostics development, current pipeline of diagnostics, market dynamics, WHO policies on new diagnostics, and challenges for scale-up
  • designs to evaluate impact of new tests on clinical decision-making, therapeutic choices, and patient-important outcomes
  • meta-analyses of diagnostic accuracy studies and GRADE approach to diagnostic policies
  • principles of implementation research, collecting evidence for scale-up, cost-effectiveness analyses and modeling studies in TB diagnostics

 


Target Audience

  • National TB Program managers and National Reference Lab managers
  • Clinicians and nurses
  • Researchers, students, trainees, fellows and academics involved in TB diagnostics research
  • Product manufacturers
  • Funding agencies
  • Product development partnerships
  • Policy makers and public health implementers
  • Community advocates and civil society

 


Enrolment

Maximum of 100 participants.